Diagnostic Features and Selection of Hypolipidemic Therapy in Patients with Coronary Artery Disease with “Possible” Familial Hypercholesterolemia

Keywords: atherosclerosis, low-density lipoproteins, diabetes, hypothyroidism, obesity, hypolipidemic therapy


The aim. To optimize the diagnostic algorithm for patients with true “possible” familial hypercholesterolemia (FH) and differential diagnosis with hypercholesterolemia on the background of comorbid endocrinopathies for selection of optimal hypolipidemic therapy.

Materials and methods. We examined 130 patients with hypercholesterolemia and comorbid pathology (type 2 diabetes mellitus, hypothyroidism, obesity grade II-III). In each group, subgroups with low-density lipoproteins (LDL) ≥5 mmol/l were selected and followed up on the background of maximum tolerated doses of statins in combination with therapy aimed to compensate comorbid pathology. The control group consisted of 20 patients with verified FH.

Results and discussion. Combined dyslipidemia was detected in groups 1 and 3, pure hypercholesterolemia in group 2. Direct correlations between lipid profile and comorbid pathology characteristics were revealed. Patients of the subgroups with “possible” FH had higher atherogenicity of the lipid profile associated with comorbid pathology destabilization and high percentage of atherosclerosis of carotid and coronary arteries. According to the results of the follow-up, it was established that statin therapy and comorbid pathology compensation led to the achievement of target levels of LDL (group 3) or a reduction of LDL by 50% (group 1, 2). In patients of the control group, statin therapy with maximally tolerated doses did not show such results.

Conclusions. The cohort of patients defined as having “possible” FH is heterogeneous and may include patients with secondary dyslipidemia on the background of comorbid pathology destabilization, timely verification and treatment of which contributes to achieving the goals of lipid-lowering therapy. Taking into account that only obese patients reached the target level of LDL <1.8 mmol/l, combined lipid-lowering therapy is recommended for patients with hypothyroidism and diabetes. Refractoriness to statin therapy in patients with verified “possible” FH emphasizes the need for combined lipid-lowering therapy (ezetimibe, PCSK9 inhibitors).


  1. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88. https://doi.org/10.1093/eurheartj/ehz455. Erratum in: Eur Heart J. 2020;41(44):4255.
  2. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. https://doi.org/10.1093/eurheartj/ehab484
  3. Mitchenko OI, Romanov VY, Chulaevska NM, Timokhova KO. [Familial hypercholesterolemia: etiopatho genesis, diagnosis, treatment and state of the problem in Ukraine]. Ukrainian Journal of Cardiology. 2019;26(4):23-31. Ukrainian. https://doi.org/10.31928/1608-635X-2019.4.2331
  4. Vallejo-Vaz AJ, Dharmayat K, Stevens C, Lyons A, Brandts J, Catapano AL, et al. Characteristics of adults with heterozygous familial hypercholesterolaemia stratified by gender: Preliminary analysis from the EAS FHSC Global Registry on over 36,000 cases of familial hypercholesterolaemia. Atherosclerosis. 2020;315:E13. https://doi.org/10.1016/j.atherosclerosis.2020.10.052
  5. EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet. 2021;398(10312):1713-25. https://doi.org/10.1016/S0140-6736(21)01122-3
  6. Revaiah PC, Bootla D, Vemuri KS, Nevali KP, Ghosh S, Sharma YP, et al. Left main revascularization with optical coherence tomography in a young male with newly diagnosed homozygous familial hypercholesterolemia. J Cardiol Cases. 2021;25(1):14-8. https://doi.org/10.1016/j.jccase.2021.05.011
  7. Ungar L, Sanders D, Becerra B, Barseghian A. Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied. Front Cardiovasc Med. 2018;5:116. https://doi.org/10.3389/fcvm.2018.00116
  8. Ray KK, Reeskamp LF, Laufs U, Banach M, Mach F, Tokgözoğlu LS, et al. Combination lipid-lowering therapy as first-line strategy in very high-risk patients. Eur Heart J. 2022;43(8):830-3. https://doi.org/10.1093/eurheartj/ehab718
  9. Rudenko AV, Mitchenko OI. [Ischemic heart disease in patients with diabetes]. Kyiv: Agat-Print; 2016. Ukrainian.
  10. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al.; ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255-323. https://doi.org/10.1093/eurheartj/ehz486
  11. Mavromati M, Jornayvaz FR. Hypothyroidism-Associated Dyslipidemia: Potential Molecular Mechanisms Leading to NAFLD. Int J Mol Sci. 2021;22(23):12797. https://doi.org/10.3390/ijms222312797
  12. Vekic J, Zeljkovic A, Stefanovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V. Obesity and dyslipidemia. Metabolism. 2019;92:71-81. https://doi.org/10.1016/j.metabol.2018.11.005
How to Cite
Mitchenko, O. I., Timokhova, K. O., & Chulaievska, N. M. (2022). Diagnostic Features and Selection of Hypolipidemic Therapy in Patients with Coronary Artery Disease with “Possible” Familial Hypercholesterolemia. Ukrainian Journal of Cardiovascular Surgery, 30(3), 50-59. https://doi.org/10.30702/ujcvs/22.30(03)/MT041-5059